drugset / Trial / NCT01074307

A Prospective, Open-labeled, Multi-centric Trial in Subjects With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea

NCT01074307

Phase 4 Completed 180 enrolled Merck KGaA, Darmstadt, Germany Merck Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a prospective, open-labeled, multi-centric trial to evaluate the effect of bisoprolol (between low dose and high dose) on surrogate markers of heart failure in Korea.

Timeline

Start
2009-10
Primary completion
2012-08
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Bisoprolol Other / unclassified 2.5 mg Oral
Subject Bisoprolol Other / unclassified 10 mg Oral